WallStSmart

IQVIA Holdings Inc (IQV)vsiSpecimen Inc (ISPC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IQVIA Holdings Inc generates 3641976% more annual revenue ($16.98B vs $466,300). IQV leads profitability with a 8.1% profit margin vs 0.0%. IQV earns a higher WallStSmart Score of 55/100 (C).

IQV

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 6.0Quality: 3.0
Piotroski: 2/9Altman Z: 1.23

ISPC

Avoid

18

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 4.0Quality: 4.5
Piotroski: 3/9Altman Z: -15.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IQVUndervalued (+11.9%)

Margin of Safety

+11.9%

Fair Value

$201.21

Current Price

$261.77

$60.56 discount

UndervaluedFair: $201.21Overvalued
ISPCSignificantly Overvalued (-40.8%)

Margin of Safety

-40.8%

Fair Value

$0.22

Current Price

$1.47

$1.25 premium

UndervaluedFair: $0.22Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IQV2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.3%9/10

Every $100 of equity generates 22 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

ISPC2 strengths · Avg: 9.5/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

Areas to Watch

IQV4 concerns · Avg: 2.8/10
P/E RatioValuation
31.9x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-0.6%2/10

Earnings declined 0.6%

Altman Z-ScoreHealth
1.232/10

Distress zone — elevated risk

ISPC4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$3.75M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : ISPC

The strongest argument for ISPC centers on Price/Book, Debt/Equity.

Bear Case : IQV

The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.63 is elevated, increasing financial risk.

Bear Case : ISPC

The primary concerns for ISPC are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

ISPC carries more volatility with a beta of 1.64 — expect wider price swings.

IQV is growing revenue faster at 8.7% — sustainability is the question.

IQV generates stronger free cash flow (360M), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

IQV scores higher overall (55/100 vs 18/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

iSpecimen Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

iSpecimen, Inc. provides technology that connects life science researchers in need of human biofluids, tissues and living cells for their research with biospecimens available from healthcare provider organizations globally. The company is headquartered in Lexington, Massachusetts.

Visit Website →

Want to dig deeper into these stocks?